Results: 5

The risk of post-polypectomy bleeding among patients receiving antithrombotic agents: A prospective observational study

Säo Paulo med. j; 139 (3), 2021
ABSTRACT BACKGROUND: In July 2012, the Japan Gastroenterological Endoscopy Society updated their guidelines for gastroenterological endoscopy in patients receiving antithrombotic therapy. Colonoscopic polypectomy procedures are associated with a high risk of bleeding. OBJECTIVES: The present study ev...

Low dosis of alteplase, for ischemic stroke after Enchanted and its determinants, a single center experience

Arq. neuropsiquiatr; 78 (11), 2020
Abstract Background: Low-dose alteplase (LrtPA) has been shown not to be inferior to the standard-dose (SrtPA) with respect to death/disability. Objective: We aim to evaluate the percentage of patients treated with LrtPA at our center after the ENCHANTED trial and the factors associated with the use of...

Thrombolysis in acute pulmonary embolism

SUMMARY OBJECTIVES Acute pulmonary embolism (APE) is an important cause of cardiovascular mortality, due mainly to hemodynamic instability. In these cases, the recommendation is to perform some reperfusion procedure, with systemic thrombolysis being the main therapy used. However, national data evaluat...

Fibrinolíticos en tromboembolismo de pulmón: Nuevas alternativas para una indicación controvertida
Fibrinolytics in lung thromboembolism. New alternatives for a controversial prescription

Medicina (B.Aires); 78 (4), 2018
El uso de fibrinolíticos en el tromboembolismo de pulmón (TEP) es un tema de debate que ha sufrido idas y venidas desde su primera descripción en la década del 60. Esta terapia que puede liberar rápidamente la obstrucción mecánica en la arteria pulmonar, tiene la limitante del alto riesgo hemorrá...

Activador del plasminógeno tisular recombinante en el manejo de trombos cardiacos en recién nacidos

Rev. chil. pediatr; 86 (3), 2015
Introducción: La incidencia de trombos cardíacos en recién nacidos (RN) ha aumentado con el uso de catéteres venosos centrales. La trombólisis con activador del plasminógeno tisular recombinante (rTPA) se ha utilizado como alternativa a la heparina en trombos gigantes con riesgo vital y de emboliza...